You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEstazolam
Accession NumberDB01215  (APRD00955)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. [PubChem]
Structure
Thumb
Synonyms
8-chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
Estazolamum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Prosom Tab 1mgtablet1 mgoralAbbott Laboratories, Limited1993-12-311997-08-18Canada
Prosom Tab 2mgtablet2 mgoralAbbott Laboratories, Limited1993-12-311997-08-18Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Estazolamtablet1 mg/1oralTeva Pharmaceuticals USA Inc1997-07-14Not applicableUs
Estazolamtablet2 mg/1oralGolden State Medical Supply, Inc.1997-08-19Not applicableUs
Estazolamtablet2 mg/1oralTeva Pharmaceuticals USA Inc1997-07-14Not applicableUs
Estazolamtablet1 mg/1oralActavis Pharma, Inc.1997-08-19Not applicableUs
Estazolamtablet2 mg/1oralRebel Distributors Corp1997-08-19Not applicableUs
Estazolamtablet2 mg/1oralActavis Pharma, Inc.1997-08-19Not applicableUs
Estazolamtablet1 mg/1oralGolden State Medical Supply, Inc.1997-08-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EsilganTakeda
EurodinTakeda
NuctalonTakeda
ProSomNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII36S3EQV54C
CAS number29975-16-4
WeightAverage: 294.738
Monoisotopic: 294.067224079
Chemical FormulaC16H11ClN4
InChI KeyInChIKey=CDCHDCWJMGXXRH-UHFFFAOYSA-N
InChI
InChI=1S/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2
IUPAC Name
12-chloro-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,8,11,13-hexaene
SMILES
ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Phenyl-1,3,4-triazole
  • Phenyl-1,2,4-triazole
  • Phenyltriazole
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Triazole
  • Azole
  • Ketimine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Imine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.
PharmacodynamicsEstazolam, a triazolobenzodiazepine derivative, is an oral hypnotic agent with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.
Mechanism of actionBenzodiazepines bind nonspecifically to benzodiazepine receptors, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
Related Articles
AbsorptionTablets have been found to be equivalent in absorption to an orally administered solution of estazolam. In healthy subjects who received up to three times the recommended dose, peak estazolam plasma concentrations occurred within two hours after dosing (range 0.5 to 6.0 hours) and were proportional to the administered dose, suggesting linear pharmacokinetics over the dosage range tested.
Volume of distributionNot Available
Protein binding93% protein bound, independant of concentration.
Metabolism

Extensively metabolized in the liver. In vitro studies with human liver microsomes indicate that the biotransformation of estazolam to the major circulating metabolite 4-hydroxy-estazolam is mediated by cytochrome P450 3A (CYP3A).

SubstrateEnzymesProduct
Estazolam
Not Available
4-hydroxy-estazolamDetails
Route of eliminationEstazolam is extensively metabolized. The elimination of the parent drug takes place via hepatic metabolism of estazolam to hydroxylated and other metabolites that are eliminated largely in the urine both free and conjugated. Less than 5% of a 2 mg dose of estazolam was excreted unchanged in the urine, with only 4% of the dose appearing in the feces. Radiolabel mass balance studies indicate that the main route of excretion is via the kidneys. After 5 days, 87% of the administered radioactivity was excreted in human urine. Less than 4% of the dose was excreted unchanged.
Half lifeThe range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include confusion, depressed breathing, drowsiness and eventually coma, lack of coordination, and slurred speech.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9796
Caco-2 permeable+0.8427
P-glycoprotein substrateNon-substrate0.5939
P-glycoprotein inhibitor INon-inhibitor0.7883
P-glycoprotein inhibitor IIInhibitor0.7786
Renal organic cation transporterInhibitor0.7784
CYP450 2C9 substrateNon-substrate0.8367
CYP450 2D6 substrateNon-substrate0.9081
CYP450 3A4 substrateSubstrate0.674
CYP450 1A2 substrateInhibitor0.8989
CYP450 2C9 inhibitorInhibitor0.822
CYP450 2D6 inhibitorNon-inhibitor0.8586
CYP450 2C19 inhibitorInhibitor0.6571
CYP450 3A4 inhibitorNon-inhibitor0.6818
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8676
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7126
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.0584 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9752
hERG inhibition (predictor II)Non-inhibitor0.8944
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral1 mg/1
Tabletoral2 mg/1
Tabletoral1 mg
Tabletoral2 mg
Prices
Unit descriptionCostUnit
Prosom 2 mg tablet1.71USD tablet
Prosom 1 mg tablet1.53USD tablet
Estazolam 2 mg tablet0.96USD tablet
Estazolam 1 mg tablet0.86USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point228-229Hester, J.B. Jr.; U.S. Patent 3,701,782; October 31, 1972; assigned to The Upjohn Co.
water solubilityPractically insoluble (1.5 mg/L)Not Available
logP4.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0423 mg/mLALOGPS
logP1.72ALOGPS
logP2.09ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)18.4ChemAxon
pKa (Strongest Basic)4.97ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.07 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity94.44 m3·mol-1ChemAxon
Polarizability29.83 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4u-4590000000-dbd088d66293b3b539c3View in MoNA
References
Synthesis Reference

Hester, J.B. Jr.; U.S. Patent 3,701,782; October 31, 1972; assigned to The Upjohn Co.

General References
  1. Watanabe S, Ohta H, Sakurai Y, Takao K, Ueki S: [Electroencephalographic effects of 450191-S and its metabolites in rabbits with chronic electrode implants]. Nihon Yakurigaku Zasshi. 1986 Jul;88(1):19-32. [PubMed:3758874 ]
  2. Oishi R, Nishibori M, Itoh Y, Saeki K: Diazepam-induced decrease in histamine turnover in mouse brain. Eur J Pharmacol. 1986 May 27;124(3):337-42. [PubMed:3089825 ]
  3. Usami N, Yamamoto T, Shintani S, Ishikura S, Higaki Y, Katagiri Y, Hara A: Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5. [PubMed:11995921 ]
External Links
ATC CodesN05CD04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Estazolam is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Estazolam is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Estazolam is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Estazolam is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Estazolam is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Estazolam is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Estazolam.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Estazolam is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Estazolam.
AminophyllineThe therapeutic efficacy of Estazolam can be decreased when used in combination with Aminophylline.
AmiodaroneThe serum concentration of Estazolam can be increased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Estazolam is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Estazolam is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Estazolam is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Estazolam is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Estazolam is combined with Amperozide.
AprepitantThe serum concentration of Estazolam can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Estazolam is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Estazolam is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Estazolam is combined with Asenapine.
AtazanavirThe serum concentration of Estazolam can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Estazolam can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Azaperone.
AzelastineEstazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Estazolam.
BaclofenThe risk or severity of adverse effects can be increased when Estazolam is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Estazolam is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Estazolam.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Estazolam is combined with Benzyl alcohol.
BexaroteneThe serum concentration of Estazolam can be decreased when it is combined with Bexarotene.
BoceprevirThe serum concentration of Estazolam can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Estazolam can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Estazolam can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Estazolam is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Estazolam.
BrimonidineThe risk or severity of adverse effects can be increased when Estazolam is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Estazolam is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Estazolam is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Estazolam.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Estazolam.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Estazolam.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Estazolam.
ButacaineThe risk or severity of adverse effects can be increased when Estazolam is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Estazolam is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Estazolam is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Estazolam is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Estazolam.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Estazolam.
CarbinoxamineThe risk or severity of adverse effects can be increased when Estazolam is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Estazolam is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Estazolam is combined with Carisoprodol.
CeritinibThe serum concentration of Estazolam can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Estazolam is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Estazolam is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Estazolam.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Estazolam.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Estazolam.
ChlorphenamineThe risk or severity of adverse effects can be increased when Estazolam is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Estazolam.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Estazolam is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Estazolam.
CitalopramThe risk or severity of adverse effects can be increased when Estazolam is combined with Citalopram.
ClarithromycinThe serum concentration of Estazolam can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Estazolam can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Estazolam is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Estazolam is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Estazolam is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Estazolam is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Estazolam is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Estazolam is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Estazolam is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Estazolam.
ClotrimazoleThe metabolism of Estazolam can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Estazolam.
CobicistatThe serum concentration of Estazolam can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Estazolam.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Estazolam.
ConivaptanThe serum concentration of Estazolam can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Estazolam can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Estazolam is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Estazolam.
CyclosporineThe metabolism of Estazolam can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Estazolam is combined with Cyproheptadine.
DabrafenibThe serum concentration of Estazolam can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Estazolam is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Estazolam.
DapoxetineThe risk or severity of adverse effects can be increased when Estazolam is combined with Dapoxetine.
DarunavirThe serum concentration of Estazolam can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Estazolam can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Estazolam can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Estazolam can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Estazolam is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Estazolam.
DesipramineThe risk or severity of adverse effects can be increased when Estazolam is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Estazolam is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Estazolam is combined with Detomidine.
DexamethasoneThe serum concentration of Estazolam can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Estazolam is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Estazolam.
DextromoramideThe risk or severity of adverse effects can be increased when Estazolam is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Estazolam.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Estazolam.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Estazolam.
DifenoxinThe risk or severity of adverse effects can be increased when Estazolam is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Estazolam is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Estazolam can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Estazolam is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Estazolam is combined with Dihydromorphine.
DiltiazemThe metabolism of Estazolam can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Estazolam is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Estazolam.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Estazolam.
DoramectinThe risk or severity of adverse effects can be increased when Estazolam is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Estazolam is combined with Doxepin.
DoxycyclineThe metabolism of Estazolam can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Estazolam.
DoxylamineThe risk or severity of adverse effects can be increased when Estazolam is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Estazolam is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Estazolam.
DronedaroneThe metabolism of Estazolam can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Estazolam.
DrotebanolThe risk or severity of adverse effects can be increased when Estazolam is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Estazolam.
DyphyllineThe therapeutic efficacy of Estazolam can be decreased when used in combination with Dyphylline.
EcgonineThe risk or severity of adverse effects can be increased when Estazolam is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Estazolam is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Estazolam can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Estazolam is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Estazolam.
EntacaponeThe risk or severity of adverse effects can be increased when Estazolam is combined with Entacapone.
EnzalutamideThe serum concentration of Estazolam can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Estazolam can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Estazolam is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Estazolam can be decreased when it is combined with Eslicarbazepine acetate.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Estazolam.
EthanolEstazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Estazolam.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Estazolam.
EthosuximideThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Estazolam is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Estazolam is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Estazolam.
EtoperidoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Estazolam is combined with Etorphine.
EtravirineThe serum concentration of Estazolam can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Estazolam is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Estazolam is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Estazolam is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Estazolam is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Estazolam.
FexofenadineThe risk or severity of adverse effects can be increased when Estazolam is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Estazolam is combined with Flibanserin.
FluconazoleThe metabolism of Estazolam can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Estazolam is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Estazolam is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Estazolam is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Estazolam.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Estazolam.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Estazolam.
FluspirileneThe risk or severity of adverse effects can be increased when Estazolam is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Estazolam is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Estazolam is combined with Fluvoxamine.
FluvoxamineThe metabolism of Estazolam can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Estazolam can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Estazolam can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Estazolam.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Estazolam.
FospropofolThe risk or severity of adverse effects can be increased when Estazolam is combined with Fospropofol.
Fusidic AcidThe serum concentration of Estazolam can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Estazolam.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Estazolam is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Estazolam is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Estazolam is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Estazolam is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Estazolam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Estazolam.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Estazolam.
HeroinThe risk or severity of adverse effects can be increased when Estazolam is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Estazolam is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Estazolam.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Estazolam.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Estazolam.
HydroxyzineThe risk or severity of adverse effects can be increased when Estazolam is combined with Hydroxyzine.
IdelalisibThe serum concentration of Estazolam can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Iloperidone.
ImatinibThe metabolism of Estazolam can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Estazolam is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Estazolam is combined with Indalpine.
IndinavirThe serum concentration of Estazolam can be increased when it is combined with Indinavir.
IsavuconazoniumThe metabolism of Estazolam can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Estazolam.
IsradipineThe metabolism of Estazolam can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Estazolam can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Estazolam can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Estazolam is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Ketobemidone.
KetoconazoleThe serum concentration of Estazolam can be increased when it is combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Estazolam is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Estazolam is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Estazolam.
LevocabastineThe risk or severity of adverse effects can be increased when Estazolam is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Estazolam is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Estazolam is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Estazolam is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Estazolam is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Estazolam.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Estazolam.
LithiumThe risk or severity of adverse effects can be increased when Estazolam is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Estazolam is combined with Lofentanil.
LopinavirThe serum concentration of Estazolam can be increased when it is combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Estazolam is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Estazolam.
LovastatinThe metabolism of Estazolam can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Estazolam.
Lu AA21004The risk or severity of adverse effects can be increased when Estazolam is combined with Lu AA21004.
LuliconazoleThe serum concentration of Estazolam can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Estazolam.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Estazolam is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Estazolam is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Estazolam is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Estazolam is combined with Medetomidine.
MefloquineThe therapeutic efficacy of Estazolam can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Estazolam.
MelperoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Estazolam.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Estazolam.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Estazolam.
MetaxaloneThe risk or severity of adverse effects can be increased when Estazolam is combined with Metaxalone.
MethadoneEstazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Estazolam.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Estazolam is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Estazolam is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Estazolam is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Estazolam.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Estazolam is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Estazolam.
MethsuximideThe risk or severity of adverse effects can be increased when Estazolam is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Estazolam.
MetyrosineEstazolam may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Estazolam can be decreased when used in combination with Mianserin.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Estazolam.
MifepristoneThe metabolism of Estazolam can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Estazolam is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Estazolam.
MirtazapineEstazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Estazolam.
MitotaneThe serum concentration of Estazolam can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Estazolam can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Estazolam.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Estazolam.
NabiloneThe risk or severity of adverse effects can be increased when Estazolam is combined with Nabilone.
NafcillinThe serum concentration of Estazolam can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Estazolam.
NefazodoneThe serum concentration of Estazolam can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Estazolam can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Estazolam can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Estazolam can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Estazolam can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Estazolam is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Estazolam is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Estazolam is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Estazolam.
OlaparibThe metabolism of Estazolam can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Estazolam is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Estazolam.
OpiumThe risk or severity of adverse effects can be increased when Estazolam is combined with Opium.
OrlistatThe serum concentration of Estazolam can be decreased when it is combined with Orlistat.
OrphenadrineEstazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Estazolam.
OsanetantThe risk or severity of adverse effects can be increased when Estazolam is combined with Osanetant.
OsimertinibThe serum concentration of Estazolam can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Estazolam.
OxprenololThe risk or severity of adverse effects can be increased when Estazolam is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Estazolam.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Estazolam.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Estazolam.
PalbociclibThe serum concentration of Estazolam can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Paliperidone.
ParaldehydeEstazolam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Estazolam.
ParoxetineThe risk or severity of adverse effects can be increased when Estazolam is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Estazolam.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Estazolam.
PerampanelThe risk or severity of adverse effects can be increased when Estazolam is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Estazolam is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Estazolam.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Estazolam.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Estazolam.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Estazolam is combined with Phenoxyethanol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Estazolam.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Estazolam.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Estazolam.
PipamperoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Estazolam is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Estazolam is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Estazolam is combined with Pomalidomide.
PosaconazoleThe serum concentration of Estazolam can be increased when it is combined with Posaconazole.
PramipexoleEstazolam may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Estazolam is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Estazolam is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Estazolam.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Estazolam.
PrimidoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Estazolam.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Estazolam.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Estazolam.
PromethazineThe risk or severity of adverse effects can be increased when Estazolam is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Estazolam.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Estazolam.
PropoxycaineThe risk or severity of adverse effects can be increased when Estazolam is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Estazolam is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Estazolam is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Estazolam is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Estazolam is combined with Quetiapine.
RamelteonThe risk or severity of adverse effects can be increased when Estazolam is combined with Ramelteon.
RanolazineThe metabolism of Estazolam can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Estazolam.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Estazolam.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Estazolam.
RifabutinThe metabolism of Estazolam can be increased when combined with Rifabutin.
RifampicinThe metabolism of Estazolam can be increased when combined with Rifampicin.
RifapentineThe metabolism of Estazolam can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Estazolam.
RitonavirThe serum concentration of Estazolam can be increased when it is combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Estazolam is combined with Romifidine.
RopiniroleEstazolam may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Estazolam.
RotigotineEstazolam may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Estazolam.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Estazolam is combined with S-Ethylisothiourea.
SaquinavirThe serum concentration of Estazolam can be increased when it is combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Estazolam is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Estazolam.
SertindoleThe risk or severity of adverse effects can be increased when Estazolam is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Estazolam is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Estazolam is combined with Sevoflurane.
SildenafilThe metabolism of Estazolam can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Estazolam can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Estazolam can be increased when it is combined with Simeprevir.
Sodium oxybateEstazolam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Estazolam.
St. John's WortThe serum concentration of Estazolam can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Estazolam is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Estazolam.
SulfisoxazoleThe metabolism of Estazolam can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Estazolam.
SuvorexantThe risk or severity of adverse effects can be increased when Estazolam is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Estazolam is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Estazolam is combined with Tasimelteon.
TeduglutideThe serum concentration of Estazolam can be increased when it is combined with Teduglutide.
TelaprevirThe serum concentration of Estazolam can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Estazolam can be increased when it is combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Estazolam.
TetrabenazineThe risk or severity of adverse effects can be increased when Estazolam is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Estazolam is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Estazolam is combined with Tetrodotoxin.
ThalidomideEstazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Estazolam.
TheophyllineThe therapeutic efficacy of Estazolam can be decreased when used in combination with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Estazolam.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Estazolam.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Estazolam.
ThiothixeneThe risk or severity of adverse effects can be increased when Estazolam is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Estazolam is combined with Tiagabine.
TiclopidineThe metabolism of Estazolam can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Estazolam is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Estazolam is combined with Tizanidine.
TocilizumabThe serum concentration of Estazolam can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Estazolam is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Estazolam is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Estazolam.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Estazolam is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Estazolam.
TrazodoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Estazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Estazolam.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Estazolam.
TrimipramineThe risk or severity of adverse effects can be increased when Estazolam is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Estazolam is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Estazolam.
VenlafaxineThe metabolism of Estazolam can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Estazolam can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Estazolam is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Vilazodone.
VoriconazoleThe serum concentration of Estazolam can be increased when it is combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Estazolam is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Estazolam is combined with Xylazine.
YohimbineThe therapeutic efficacy of Estazolam can be decreased when used in combination with Yohimbine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Estazolam.
ZiconotideThe risk or severity of adverse effects can be increased when Estazolam is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Estazolam is combined with Zimelidine.
ZiprasidoneThe metabolism of Estazolam can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Estazolam is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Estazolam is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Estazolam.
ZonisamideThe risk or severity of adverse effects can be increased when Estazolam is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Estazolam.
ZotepineThe risk or severity of adverse effects can be increased when Estazolam is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Estazolam is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol. 1978 Apr 1;48(3):263-70. [PubMed:639854 ]
  2. Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601. [PubMed:2889803 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23